ArticleGastroenterology2026
Quorum-Sensing Molecules Are Elevated in Long-Standing Ulcerative Colitis and Are Linked to the Development of Colitis-Associated Cancer.
Article in Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microbiota-Associated Amino Acid Metabolites in Inflammatory Bowel Disease: Emerging Key Players in the Host-Microbe Interface.Microorganisms · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
BACKGROUND &
aimsChronic colonic inflammation can lead to colitis-associated cancer (CAC) in ulcerative colitis (UC) patients. The host-microbiome interface plays a critical role in CAC development. Quorum-sensing molecules (QSMs) are bacterial products that regulate bacterial processes. We investigated whether QSMs are related to risk factors for CAC in UC patients and drive CAC development in mouse models.
methodsBlood samples from UC patients and mouse models of CAC (azoxymethane-dextran sodium sulfate) were analyzed for 3 bacterial QSM classes: short-chain n-acyl homoserine lactones (scAHLs) and long-chain n-acyl homoserine lactones and autoinducer-2. CAC mouse models (specific pathogen-free and germ-free) were challenged with C6-scAHL. QSM levels, colitis-associated tumor development, microbiome composition, and metabolome profiles were examined. Murine and human colonic organoid cultures were used to examine C6-scAHL-driven cytokine production.
resultsSerum scAHL levels were higher in UC patients than in healthy controls. UC patients with inflammation and ≥10 years of disease had elevated autoinducer-2 levels. Systemic C6-scAHL administration to a CAC mouse model increased tumor number and size and was associated with microbiome and metabolome changes similar to those in inflammatory settings. C6-scAHL administration also promoted tumor development in germ-free mice. In colonoids derived from mice and UC patients, C6-scAHL increased tumorigenic and proinflammatory cytokine production.
conclusionsThe bacterial QSM C6-scAHL is elevated in UC patients with CAC risk factors. C6-scAHL promotes colon tumor development in mice and drives proinflammatory and protumorigenic cytokine production in vitro. Our findings highlight a previously unexplored pathogenetic pathway linking the microbiome to CAC development and suggest targets to modify CAC risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.